目的 探讨醒脑静注射液联合依达拉奉治疗急性脑梗死的临床疗效。方法 选取2020年2月-2021年2月新郑市人民医院收治的98例急性脑梗死患者，按照随机数字表法分为对照组和治疗组，每组各49例。对照组患者静脉滴注依达拉奉注射液，将30 mg加入到0.9%氯化钠注射液100 mL，2次/d。治疗组在对照组基础上静脉滴注醒脑静注射液，20 mL加入到5%葡萄糖注射液250 mL，1次/d。两组均连续治疗14 d。观察两组的临床疗效，比较两组相关评分、血清学指标和血清炎性因子水平的变化情况。结果 治疗后，治疗组总有效率是98.0%，显著高于对照组的75.5%（P<0.05）。治疗后，两组NIHSS评分均显著降低，但GCS评分升高（P<0.05）；治疗后，治疗组NIHSS评分低于对照组，而GCS评分高于对照组（P<0.05）。治疗后，两组神经特异性蛋白100β（S100β）、神经元特异性烯醇化酶（NSE）水平均显著降低，但脑源性神经营养因子（BDNF）水平显著升高（P<0.05）；治疗后，治疗组血清学指标改善优于对照组（P<0.05）。治疗后，两组超敏C-反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）及白细胞介素-1（IL-1β）水平均较治疗前显著降低（P<0.05）；治疗后，治疗组血清炎性因子低于对照组（P<0.05）。结论 醒脑静注射液联合依达拉奉治疗急性脑梗死效果明显，可有效降低机体炎性因子水平，改善脑血管功能，具有较高的安全性，值得临床推广应用。

Objective To investigate the clinical effect of Xingnaojing Injection combined with edaravone in treatment of acute cerebral infarction. Methods A total of 98 patients with acute cerebral infarction admitted to Xinzheng People's Hospital from February 2020 to February 2021 were selected and divided into control group and treatment group according to random number table method, with 49 cases in each group. Patients in the control group were iv administered with Edaravone Injection, 30 mg was added to 0.9% sodium chloride injection 100 mL, twice daily. Patients in the treatment group were iv administered with Xingnaojing Injection on the basis of the control group, 20 mL was added to 5% glucose injection 250 mL, once daily. Both groups were treated for 14 d. The clinical efficacy of the two groups were observed, and the changes of related scores, serological indexes and serum inflammatory factors were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 98.0%, significantly higher than that of the control group (75.5%) (P<0.05). After treatment, NIHSS score was significantly decreased in both groups, but GCS score was increased (P<0.05). After treatment, NIHSS score in the treatment group was lower than that in the control group, while GCS score was higher than that in the control group (P<0.05). After treatment, the levels of neurospecific protein 100β (S100β) and neuron specific enolase (NSE) were significantly decreased, but the level of brain-derived neurotrophic factor (BDNF) was significantly increased in both groups (P<0.05). After treatment, serological indexes in the treatment group were better than those in the control group (P<0.05). After treatment, the levels of hypersensitive C-reactive protein (HS-CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 (IL-1β) in two groups were significantly decreased compared with before treatment (P<0.05). After treatment, the serum inflammatory factors in the treatment group were lower than those in the control group (P<0.05). Conclusion Xingnaojing Injection combined with edaravone has obvious effect in treatment of acute cerebral infarction, and can effectively reduce the body inflammatory factor levels, and can improve cerebrovascular function with high safety, which is worthy of clinical application.

R971